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Abstract
Asthma, obesity, and irrational use of antibiotics early in a life can be considered to be 
the three epidemics of modern times, which encourage one another and whose base is 
the loss of bioavailability. Disruption of the intestinal microbiome early in the life is the 
basis for the development of metabolic diseases, allergic immunological diseases, and 
high mortality rate due to infection with resistant strains of bacteria. During the irratio‐
nal use of penicillin and macrolides postnatally, the composition of the intestinal micro‐
biota and its functions change 12–24 months after the antibiotics treatment, the settlement 
of advantage intestinal flora with probiotic microorganisms is delayed, the maturation 
of the intestinal mucosa is compromised. Respiratory and systemic inflammation is 
strongly influenced by the rich adipocyte metabolism so that the treatment of these chil‐
dren is complex, and their asthma often remains only partially controlled. The phenotype 
“obese asthma” is characterized by a steroid and bronchodilator resistance. Therapeutic 
solution could be the body weight reducing, vitamin D3 substitution, and antileukotriene 
application. The prophylactic therapy of this asthma, using macrolides for a long time, 
should be supported, mandatory, with the substitution of probiotic/synbiotic during, and 
at least 6–9 months after discontinuation of therapy with macrolide.
Keywords: asthma, overweight, macrolide, prophylaxis, probiotic
1. Introduction
Pediatricians are nowadays increasingly more convinced by the data reported in the medical 
literature that the crucial time for the inception of asthma and obesity is during the childhood. 
What is it that happens during the 1st years of a child's life that produces changes in the lung 
and immune system, which predisposes the child to a lifetime of chronic symptoms related 
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to the “obese asthma” phenotype? This phenotype has previously been discussed [1, 2] as a 
unique, but today we are closer to the opinion that there is a distinct phenotype. Each of these 
diseases, asthma and obesity, is complex per se, modified by multiple factors, followed by 
complex inflammatory and immunological interactions, and often shared comorbidities; and, 
both diseases share similar lifestyle factors [1]. Until recently, many authors have explored 
a number of hypotheses about the mechanisms of their association including inflammation, 
gastro‐esophageal reflux, and mechanical factors. Nowadays, we can consider the one more 
mechanism to be responsible for their association, i.e., the significant influence of irrational 
use of antibiotics (penicillin, macrolides) in the youngest children under 3 years of age [3, 4]. 
It is known that children of this age predominantly suffer from viral and atypical respiratory 
infection, which is, in practice, often treated with macrolides.
Macrolides, particularly, modify the microbiota and their functions, as well as the antibiotic 
resistance of the intestinal microbiota, and they are the strongest drive of interindividual dif‐
ferences in microbiota composition even 12–24 months after the course, as well as the drive 
of microbiota richness and maturity [4]. The recent study [4] has shown that, in all macrolide 
users, some advantage orders of germs (Lactobacillus, Bifidobacterium, Collinsella, Anaerostipes, 
unassigned Coriobacteriaceae) were reduced within 12–24 months while the number of side/
undesirable orders of germs increased (Lactobacillales, Bacteroides, Parabacteroides, Proteobacteria, 
Enterobacteriaceae, Eubacterium, Clostridium, Dorea). It is known that the depletion of Lactobacillus 
and Bifidobacterium with intestinal microbiota deviations and low biodiversity, in early life, con‐
tributes to an increased risk of the allergic disease [5]. The composition of CD4 T lymphocytes 
and responsiveness of invariant natural killer T (iNKT) cells on many inflammatory cytokines 
in the intestinal mucosa affect the composition and diversity of the gut microbiota [6], espe‐
cially during early life, and this may influence susceptibility to asthma later in life [7]. The com‐
mensal microbiota, achieving two mechanisms (positive‐antigenic drive and negative‐cytolytic 
depletion by CD8+T cells) profoundly depletes the iNKT cell compartment [7], plays an impor‐
tant epigenetic role in distinguishing individuals throughout life and contributes to the host 
immune status. The restricted gut flora followed with decreased microbial stimulation leads to 
the delayed immune maturation (Th2 and T regulatory) and impaired immune regulation with 
Th2‐skrewing early in life, which precedes asthma at school age [8]. The infant microbiome (gut 
microbiota and its corresponding genes) is undergone dynamic changes during the first 3 years 
of life when an adult‐like microbiome is reached [9]. In the research with mice, it was found that 
the penicillin, also, led to the ileal atrophy associated with the generally decreased expression 
of genes involved in intestinal immune responses, with numerous consistencies across gender, 
i.e., reducing population of CD4 IL17 or IL22 in the ileum and colon [10].
Besides this, poor intestinal microbiota cannot provide adequate activity of the bile‐salt 
hydrolase so there is no reduction in the host body weight, insulin resistance, and blood cho‐
lesterol [4].
2. The mechanisms of association between asthma and obesity
The pathogenesis of asthma in obese children and, vice versa, the obesity in asthmatics are 
poorly understood and, until recently, labeled as a pathogenesis of “obese asthmatics” [2]. 
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Today, we know that the obesity had its origin in utero [1, 8]. Suboptimal nutrition in utero 
during the first two trimesters (despite normal postnatal nutrition and followed by catch‐up 
growth in the first several years of life) causes obesity and consequently metabolic syndrome 
in children [8, 11]. Frey et al. [12] concluded that the children born with a low and high birth 
weight have an almost same increased risk of obesity later in life.
According to one hypothesis, the first risk factors for obesity in childhood asthma and “non‐
pure eosinophilic childhood asthma” [1, 13] are younger gestational age at birth and higher 
infant weight gain. For the “obese asthma,” there is no sufficient evidence of a noneosino‐
philic pattern of inflammation, with subgroup of asthmatics demonstrating IL8‐driven neu‐
trophilic airway inflammation [13]. In such cases, there is a high mitogen‐activated protein 
kinase (MAPK) and 8‐isoprostane level, which all together correlate with increased leptin, 
increased Th 1 cytokines (IL2, tumor necrosis factor (TNF)‐alpha, IL6, INF‐gamma, and IL1‐
beta, IL8), increased tryptase, expressed leptin and adiponectin receptors in bronchial and 
alveolar epithelial cells, and simultaneously, they correlate with low adiponectin, decreased 
Th2 cytokines (IL4, IL5, and IL13), decreased Treg cells, decreased eosinophils, and decreased 
M2 macrophages [14]. Leptin and TNF‐alpha establish a positive feedback mechanism. Leptin 
promotes activation toward Th1 phenotype, increases production of interferon (INF)‐gamma, 
and promotes monocytes and alveolar macrophage activation, but decreases Th2 cytokines 
production. Simultaneously, leptin exhibits antiapoptotic properties on neutrophils via NF‐
kB and MEK1/2 MAPK pathway, and so it promotes neutrophil survival. These, all together, 
immunological occasions could modify airway function and lead to asthma with special air‐
way inflammation [1, 13], accompanied, in the same time, with a low‐level chronic systemic 
inflammation [14]. The systemic inflammation in obesity upregulates the asthmatic pathway, 
and this is modified by adipokines and other systemic inflammatory markers [14]. Increased 
TNF‐alpha is responsible for airway hyperresponsiveness although data suggest little associa‐
tion with obesity [15]. However, other authors [16] consider that the adipocytes diameter is in 
a positive correlation with TNF‐alpha. The subcutaneous adipocytes may be more important 
for glucose/insulin regulation than visceral fat in obese children and women [6, 16, 17]. The 
low insulin sensitivity is followed by high exhaled breath condensate levels of malondialde‐
hyde, high exhaled nitric oxide, and low glutathione, which are some asthma markers [18, 19].
At the same time, leptin promotes angiogenesis and airway remodeling via vascular endo‐
thelial growth factor (VEGF) (released from airway muscle cells). However, metabolism 
of leptin can only partly explain the relationship that exists in the phenotype of asthma in 
obese children [13]. The next adipokine, called adiponectin, decreases in the obese, increases 
with weight loss, i.e., inversely correlates with body mass index (BMI), and can inhibit the 
production of pro‐inflammatory cytokines (IL6, TNF‐alpha), can promote the production of 
anti‐inflammatory cytokine IL1 receptor antagonist and IL10, and so can attenuate allergen‐
induced airway inflammation [13].
Furthermore, some researchers observed the intergeneration aggregation (transgeneration 
transmission) of obesity and metabolic dysfunction [11, 12]. The gestational programming 
with metabolic abnormalities leads to the changes to the epigenomics and shifts toward obe‐
sity and metabolic syndrome. This should be taken with caution because the epigenetic gene 
modifications may be reversible [11, 12]. Surely, the epigenetic alterations are induced by sub‐
optimal maternal nutrition/endocrine factors and include several factors (deoxyribonucleic 
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acid (DNA) methylation, histone modifications, chromatin remodeling, and/or regulatory 
feedback by microRNAs) that have the ability to modulate gene expression and promote the 
metabolic syndrome phenotype [13]. DNA methylation prevents gene access to transcription 
factors into mRNA and promotes other epigenetic changes. Epigenetic modification of genes 
in immune cells responsible for disease/disorder is launched by diet, microbiome, and envi‐
ronmental exposures, and can have long‐lasting effects on immune responses related to aller‐
gic disease. We should not forget that prenatal exposures can have the potential to modify the 
development of atopic diseases during childhood.
Moreover, the possible reason for obesity in early childhood is a genetic polymorphism 
(Arg16, Gln 27, 308‐G/A, and NR3C1) [13]. Polymorphism of gene Gln27 for beta‐2‐adrener‐
gic receptors is associated with obesity and poor bronchodilator response. Polymorphism of 
308‐G/A of gene for TNF‐alpha is also associated with both obesity and asthma. Gene ADRB2 
codes the activity of adrenergic beta‐2‐receptor and is located on chromosome 5q31‐q32. Thus, 
Arg16 polymorphism of this receptor may be associated with some asthma phenotypes (noc‐
turnal, response to long‐acting beta‐2‐agonists). Polymorphism of gene NR3C1 is followed by 
the resistance of glucocorticoid receptors and difficult‐to‐control asthma. Polymorphism of 
gene on chromosome 11q13 contributes to variation of obesity phenotypes in general popula‐
tion. Moreover, it is known that single nucleotide polymorphisms within several genes influ‐
ence the development of both obesity and asthma at the genetic level [13]. We should not 
forget that chromosome 12q contains genes (12q13) for variants in vitamin D receptors and 
inflammatory cytokines in obese asthmatics [13, 14].
Atopy significantly mediates the effect of adiposity on asthma outcomes (Figure 1). However, 
the exact role of atopy or allergic airway inflammation in the “obese asthmatic” phenotype is 
currently unclear [13]. Periyalil et al. [14] found that adipocytes, macrophages, and mast cells 
secrete inflammatory cytokines, which in turn lead to systemic inflammation and negative 
effects of target organs. Allergic asthma may be followed by obesity when the children are 
Figure 1. Associations among asthma, obesity, irrational use of antibiotics and effects of probiotics/synbiotics. The solid 
arrows indicate undesirable effects. The dashed‐line arrows indicate desirable effects.
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younger than 12 years and suffer from early‐onset asthma and/or atopic eczema and/or food 
allergy in infants, that all together lead to excessive consumption of food and to modified 
asthma phenotype called “obese asthmatic” phenotype [13]. As the metabolism of adipocytes 
is rich, and the estrogen enhances eosinophil function and modulates IL4 and IL13 produc‐
tion by monocytes, the “obese asthma” phenotype is noted predominantly in prepubertal 
boys and girls, and premenopausal women, established the sex and age dependency [15–17].
According to another hypothesis, both asthma and obesity are associated with the increased 
airway oxidative stress and systemic inflammation, which is followed by lung restriction, 
reduced tidal volume (Vt), reduced cyclic loading and unloading impulses, less production 
of adenosine triphosphate (ATP) for uncoupling, i.e., unlocking of actin‐myosin latch so that 
the airway smooth muscles are in stiff state, the bronchoconstriction is very strong and with‐
out bronchodilator response [19, 20]. This is accompanied with changes in the mechanics of 
breathing [21] with low volume at end of normal expiration (FRC), especially when in supine 
position, and low the expiratory reserve volume (if BMI higher than 35), the tidal volume (Vt) 
closed to residual volume. Low forced expiratory volume in 1 second (FEV1), low forced vital 
capacity (FVC), and the ventilation/perfusion ratio mismatch are followed by barrelhocked 
chest and possible atelectasis; lung compliance is reduced, and the airway resistance rises 
so that oxygen uptake is greater (VO
2
) with high respiratory rate and work of breathing. 
Recent research study [21] has found that, within obese patients in supine position, the airway 
resistance during tidal breathing increases, but there is a difference between those with and 
without ventilatory failure. This change is mostly correlated with the visceral adipose tissue 
mass and the small airways. In effect, the authors [21, 22] argue that mass loading affects 
respiratory mechanics by other mechanisms such as altering chest wall compliance directly 
by restricting expansion and causing the respiratory system to operate on a less compliant 
part of the pressure‐volume curve.
According to the third hypothesis, the obese children often have gastroesophageal reflux dis‐
ease [23], which can worsen their asthma and vice versa. The stomach acid goes back into the 
esophagus, spills over the larynx, causes injury to the lining of the throat, airways, and lungs, 
which makes inhalation difficult and often causes a persistent cough on extraneous content, 
or acid enters the esophagus, triggers the afferent nerve reflex of coughing, causes the narrow‐
ing of airways in order to prevent the acid from entering, and the consequence is the short‐
ness of breath [24]. Neural connections between esophagus and airway through the transient 
receptor potential may contribute to that [24]. Microaspirations of small amounts of acidic 
content, over time, contribute to chronic cough and reduce laryngeal mechanosensitivity to 
air stimuli, increasing the risk of aspiration thereby, as in a vicious circle [24].
3. The pathogenesis of asthma in children who are not obese
Unlike the obese children suffering from asthma, the asthmatic children with normal body 
weight (nBW) have a different immunopathogenesis of asthma. Asthma in children with nBW 
is predominantly allergic, especially if it is associated with eczema, food allergy, and allergic rhi‐
nitis. Allergic asthma can begin during the 1st year and disappear by the 3rd year of life. In this 
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case, it is called infantile asthma. Immunopathogenesis of infantile allergic asthma [25] often is 
not typical (mediated by increased immunoglobulin E (IgE) production of IgE and eosinophilic 
airway inflammation). Postnatal sensitization to perennial inhalant allergens and frequent viral 
infections of the lower respiratory tract occur in this age. The most common trigger factors of 
the asthmatic attacks are viruses and atypical bacteria, so the asthma is accompanied by mixed 
(eosinophil/neutrophil) inflammation of the airways. In children older than 3 years with nBW, 
allergic asthma usually has a typical immunopathogenesis, with the increased IgE production, 
eosinophilic inflammation of the airways, and type I hypersensitivity response.
Certainly, in children suffering from asthma with nBW, undermined tissues integrity of the air‐
ways and/or defective function of the respiratory epithelial barrier allow penetration of aller‐
gens, viruses, bacterial toxins, and other harmful noxae, which activate the immune system 
(Figure 2) and direct toward chronic airway inflammation [25, 26]. Activation of epithelial cells 
and the release of pro‐inflammatory cytokines and chemokines (TNF‐alpha, IL13, thymic stromal 
lymphopoietin (TSLP), IL31, and IL33) lead to Th2 cell response (IVb type immune response). 
After that the apoptosis of the epithelial cells and their peeling with a supporting release of 
IFN‐gamma, TNF‐alpha, and IL32 follow. Chemokines attract inflammatory cells that interact 
with the target tissue cells. Akdis found that innate lymphoid cell type 2 (ILC2) plays a key role 
in the activation and collection of T and B cells, i.e., they are early providers of Th2 immune 
response followed by the release of IL5, IL9, and IL13 when stimulated with IL25, IL33, and TSLP 
(released from epithelial cells of mucous membranes in response to protease allergens) [25, 26].
Figure 2. Pathogenic mechanisms in asthma.
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It is known that certain interleukins (IL5, IL25, and IL33) induce eosinophilia and eosino‐
philic airway inflammation, and other interleukins (IL4 and IL13) induce local and systemic 
IgE production [25, 26]. In the phase of sensitization of a patient, FcεRI binds the allergen‐
specific IgE [25] on the surface of mast cells and basophil cells. During the repeated contact 
with the same allergen, subsequent degranulation of mast cells and basophils, which release 
the mediators of type I hypersensitivity reactions (histamine, prostaglandin D2 (PGD2), PAF, 
LTC4, LTD4, LTE4, IL3, IL4, IL5, IL13, chemokines), occurs. Effector T cell subpopulations 
(TH9, Th17, and TH22) play a partial role in inflammation, mucus production, and the tissue 
healing. Bronchial hyperreactivity, smooth muscle spasm, and activation of myofibroblasts 
are controlled by a number of cytokines (IL4, IL9, IL13, IL25, and IL33). Subsequently, collec‐
tion of inflammatory cells and increased inflammatory cascade are induced by chemokines 
and the molecules of the metabolic pathway of arachidonic acid. Angiogenesis is a sign of 
chronic inflammation and is accompanied by an increased production of VEGF and IL32. 
Survival, reactivation of migratory inflammatory cells and their interaction with tissue cells 
are mediated by IL2 and IL4 [26]. The type 2 innate lymphoid cells also produce amphiregulin 
to induce airway remodeling (Figure 2).
IL33 is a cytokine and a biomarker of innate immune response. It is expressed by epithelial 
cells, endothelial cells, eosinophils, smooth muscle, myofibroblasts, dendritic cells (DC), mac‐
rophages, and mast cells, and contributes to Th2 inflammation and bronchial hyperreactivity 
in asthma, and involves in T cell differentiation. IL33 is one of the sensing cytokines, thus sig‐
nals to the allergen‐presenting dendritic cells to take up incoming allergens and bring them 
to lymph nodes.
In the course of the immune response to a viral antigen, the signaling of factor 3 of the inter‐
feron gene regulation is defective in a child suffering from allergic asthma, which is accom‐
panied by a reduced or absent INF‐beta production, causing the absence of apoptosis and 
inhibition of the virus replication [25–27]. Since the cellular immunity is defective, viral 
nucleic acid cannot activate the toll‐like receptors (TLR3, TLR5, and TLR7) that lead to the 
virus survival, its replication, and the cytotoxic destruction of epithelial cells, which release 
the mediators that cause the exacerbations with mixed neutrophil/eosinophilic inflammation. 
The final result of INF‐beta deficiency is an increase of transforming growth factor (TGF)‐
beta, which contributes to the deregulation of Treg lymphocytes, an early proliferation and 
remodeling of the airways [27]. At the same time, FcεRI action on the precursors of dendritic 
cells is amplified, so the virus can be easily attached via a light chain of the Fab fragment of 
IgE. Recent research findings suggest that the iNKT cells promote sensitization to ubiquitous 
inhalant allergens [28], contribute to in vivo Th2 inflammatory response of the airways facili‐
tating the activity of dendritic cells, i.e., acting as adjuvants for the enhance of Th2 inflamma‐
tory cell response [29] and thereby contribute to the development of asthma and other allergic 
diseases. What else, activated DCs traffic to lymphoid organs to initiate T cell responses to the 
viruses or allergens and so contribute to further disease pathogenesis.
Th2 molecular asthma phenotypes are determined by identifying the clinical characteristics 
and biomarkers (eosinophilia and serum periostin, the concentration of exhaled nitric oxide) 
and sometimes by identifying specific molecular pathways [30]. However, non‐Th2 pheno‐
types of asthma, often asthma in obese children and sometimes infantile asthma, are still 
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poorly defined and their biomarkers (modified natural inhibitor of inducible nitric oxide syn‐
thase, asymmetric dimethylarginine in the blood) are still not routinely measured. Identifying 
phenotypes of asthma in children and adults is important so we could provide the appropri‐
ate treatment. Most children suffering from allergic asthma with nBW are successfully treated 
according to the recommendations of the Global Initiative for Asthma [31]. Most children 
suffering from the asthma with the nBW have a good response to inhaled steroids (ICS) and/
or antileukotrienes. In a small number of children, asthma is severe and requires the treat‐
ment with high‐dose of ICS. Poor response to ICS can have children with difficult to treat 
asthma, asthma induced by viruses and “obese” asthma so the treatment of these patients is 
complicated.
4. The obese and asthmatic children treated with antibiotics
The children of the youngest age predominantly suffer from viral and atypical respiratory 
infection, which is, often, mistakenly treated with antibiotics, actually, very often with mac‐
rolides. This applies, furthermore, in the children suffering from asthma with accompanying 
obesity because their asthma exacerbation, very often, triggered with virus and followed by 
the fever, is often considered to be a respiratory infection with bronchial obstruction and is 
hitherto mistakenly treated with antibiotics.
The overweight cases, the asthmatics, and the children treated with penicillin or macrolide 
(one or more times) have the microbiota with the abundance of side bacteria and long‐term 
reduction in microbial richness [4] (Figure 1). For example, one of the macrolides, the azithro‐
mycin, reduces biomarkers of not only environmental enteropathy and pathogenic intestinal 
bacteria [32, 33], but also commensal and advantage bacteria, which makes restricted (poor) 
flora. The gut microbiota with restricted flora is mediated by cytolytic CD8+ T cells with 
depleted iNKT cells that contribute to epigenetically modulating of specific host immune 
traits (defense and immunoregulation) [6]. It is known that CD8+ T cell responses are elicited 
by certain microbiota, including Listeria and Salmonella and followed by the local enteric 
mucosal stress response, which is associated with striking increases in certain chronic inflam‐
matory and autoimmune diseases [6]. Besides that azithromycin inhibits ribosomal translo‐
cation, leading to the inhibition of bacterial protein synthesis, acts bacteriostatic but may be 
bactericidal at high concentrations, modulates differentiation and lipopolysaccharide (LPS) 
induces maturation in dendritic cells but decreases transcription and activity of histone 
deacetylation‐2 promoter, which results in gene repression [32]. After macrolide [3, 4, 32, 33], 
the microbiota slowly recovers so that it establishes persistence of the antibiotic‐associated 
microbiota composition, which contributes to the persistence of metabolic changes and com‐
promises the development of a healthy immune system, so that the consequences are early 
manifestations of asthma and obesity. The mentioned effect of macrolides is not dependent 
on the age of the child [4].
The impression is that use of antibiotics during early life, linked with poor gut microbial 
diversity, drive to “preponderance” of side over advantage effects of antibiotics (macrolides 
and penicillin) [3, 4, 32, 33]. Pronouncedly, in the case of irrational use of antibiotics during 
early life, the restricted gut flora is followed by a decreased microbial stimulation, which 
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leads to the delayed immune maturation (Th2 and T regulatory) and the impaired immune 
regulation with Th2‐skrewing early in life, which precedes asthma at school age [3, 4, 8] and 
obesity early in life [10, 11, 14]. This consideration has no intention of diminishing the desired 
effects of azithromycin (attenuates Th‐1 responses following LPS or INF‐gamma stimulation 
of macrophages, shifting polarization of activated macrophages toward the alternative/anti‐
inflammatory M2‐phenotype (which plays a role in directing Th‐2 responses), inhibits IL17‐
induced IL8 and 8‐isoprostane release)—but pointing out the need for its rational application, 
the “balanced” therapy, new therapeutic modality, especially in the children suffering from 
wheezing, respiratory infections and obesity.
In the mentioned period of 12–24 months, the macrolide use is associated with the increased 
risk of asthma and it predisposes children to the antibiotic‐associated weight gain. The mac‐
rolides impact on the intestinal microbiota should be considered with mandatory prescribing 
probiotics [4], which would prevent compromising of a healthy immune system and metabo‐
lism development. It has been proven that “good” probiotic bacteria and “good” probiotic 
fungi in the mouth and intestines, sufficiently represented, are necessary to compensate 
destroyed intestinal flora during and after antibiotic therapy and for the health of children [5] 
(Figure 1). We have, also, confirmed that the use of synbiotics in the optimal period of time 
of 3–6 months can achieve adequate control of respiratory infection and allergic wheezing 
diseases in children younger than 5 years [34]. Nevertheless, we have found that the time 
necessary for the restitution of the immune balance between immunoglobulin A and immu‐
noglobulin E was 9 months in the youngest children [34]. Now, we can add a logical setting 
as hypothesis that should have been assessed in clinical trials, that the everyday application 
of synbiotic (during several months) after antibiotic using would likely prevent the obesity.
In favor of this Million's findings [35], the probiotics affect the microbiota directly by modu‐
lating its bacterial content and indirectly through bacteriocins produced by the probiotic bac‐
teria, as well as, L. plantarum and Lactobacillus gasseri (formerly named L. acidophilus) strains, 
which has an anti‐obesity effect in overweight/obese people in terms of reductions in abdomi‐
nal adiposity, body weight, and other measures. Adding a probiotic strain Bacteroidetes can 
be essential for the body weight loss in obese patients, because Bacteroidetes overgrows the 
undesirable gut strain named Firmicutes [35].
It is known that the trillions of the side microbial cells in the intestinal microbiota can contrib‐
ute to obesity by increasing energy extraction or by altering metabolic signaling and inflam‐
mation [36], and thus occupy a central role in the pathogenesis of, so far seemingly unrelated 
systemic auto‐inflammatory and metabolic disorders. As a matter of fact that the condition of 
basal immune and metabolic homeostasis is mainly controlled by the bacterial microbiome.
5. The inflammation in the “obese asthma” phenotype and 
the  possibility  of the treatment
Inflammation is the goal in the treating of childhood asthma accompanied by obesity, but 
here, inflammation is neutrophilic, with elevated leptin levels in the plasma and airways, 
predominately Th‐1‐related inflammation (IL8 driven) [13, 21], potential and IL‐17‐related 
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inflammation, enhanced inflammatory/oxidative response to leptin and decreased airway 
eosinophils. The high level of leptin stimulates the synthesis of TNF‐alpha, IL6, and prosta‐
glandins, which is the basis for a low‐grade inflammatory process that leads to the atherogen‐
esis process and early development of metabolic syndrome. The leptin receptors are reduced 
in the airways but they are represented in the visceral fat, which enables metabolic influence 
on bronchial hyperreactivity [20, 37]. Increased oxidative stress and decreased physiologic 
nitric oxide are due to low L‐arginine/asymmetric dimethylarginine ration, which overall 
contributes to bronchoconstriction [20, 21, 38, 39]. This metabolic function of smooth muscle 
in the airways contributes to a poor response to bronchodilators, poor asthma control, and 
low pulmonary function. In the “obese asthma” phenotype, increased airway oxidative stress 
and systemic inflammation are followed by reduced cycling loading and unloading impulses, 
the less production of adenosine triphosphate for uncoupling, i.e., unlocking of actin‐myosin 
latch [19, 20], so that the smooth muscles airways are in a stiff state, the bronchoconstriction 
is very strong and without bronchodilator response, i.e., the resistance to short‐acting beta‐
agonists exists.
Both conditions, asthma and obesity, associated, act to aggravate the degree of bronchodilata‐
tion after a deep inhalation, which is a mechanical airway dysfunction [37]. The mechanical 
airway dysfunction in an “obese asthma” phenotype is a consequence of restriction or reduced 
the total lung capacity, decreased expiratory reserve volume and there is a ventilation/per‐
fusion mismatch. In obese asthmatics, it is associated with increased airway inflammation 
indices. At the same time, body mass index (BMI) more than 30 was associated with a 10‐fold 
increase in odds for developing methacholine responsiveness [37, 38]. Anyhow, early onset of 
asthma is a potential risk factor for the weight gain. In the early onset category, BMI increased 
linearly for every year of having asthma since diagnosis [37]. It is still not clear whether obe‐
sity, preceding or following asthma, influences the severity of asthma and asthma control.
A special problem in the treatment of this asthma phenotype is the steroid resistance. The 
response to inhaled steroids is different according to BMI categories [39]. The oxidative stress 
contributes to the activation of MAPK, baseline TNF‐alpha in peripheral blood mononuclear 
cells and bronchoalveolar lavage cells, so that the response, for example, to dexamethasone is 
poor or does not exist. The TNF‐alpha is in a positive correlation with the adipocyte diameter, 
with which metabolism is rich. Doubtless, we can always try to treat this asthma phenotype in 
the form of fixed combinations of low doses of inhaled steroid and long‐acting beta 2 agonist.
The second reason for the steroid resistance in the “obese asthma” phenotype is, often, a low 
vitamin D level that is inversely related to BMI [40, 41]. Vitamin D performs the upregula‐
tion of IL‐10 by CD4 Treg lymphocytes, thus it exceeds steroid resistance [37] and inhibits 
the activity of DCs across the decreased LPS activation, inhibits the proliferation and fibro‐
blasts activation and inhibits the inflammatory cytokines and the airway remodeling media‐
tors secretion by the smooth muscle cells in airway, reduces the secretion of extracellular 
matrix, acts anti‐proliferatively on smooth muscles, improves the immune function in the 
lungs, upregulates the antimicrobial proteins (cathelicidin, beta‐defensin), acts anti‐inflam‐
matory, reduces the pulmonary hyperplasia, inhibits the eosinophils recruitment, promotes 
the immune tolerance [41], and reduces the IL‐17A and IL‐22 cytokine levels [42].
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The antileukotriene treatment can be successful at the certain asthmatics with the phenotype 
“obese asthma” because it controls the release of INF‐gamma and producing of myofibro‐
blasts types I and II well [31].
The antineutrophil drugs, such as macrolides and dapsone (diaminodiphenyl sulfone), did 
not give the expected results for the “obese asthma” phenotype control [31]. Furthermore, the 
advantage of anti‐inflammatory role of macrolides is in conflict with its side, already com‐
mented, effects on intestinal mucosa in young children. Because of this, we must find other 
drugs to treat the “obese asthma” phenotype in the youngest children, such as, perhaps, anti‐
cytokines or biological agent [12]. However, the anti‐TNF‐alpha therapies have not yet been 
approved for children, but only for adults [38]. The bariatric surgery is the only aggressive 
attempt.
6. Conclusion
Well‐known and safe recommendations for the “obese asthma” phenotype control are, 
without doubt, the cutoff of the vicious cycle of childhood obesity/asthma, which should be 
reached with more physical activity and less desire for food [43, 44]. Afterward, the substitu‐
tion of D3 vitamin may be decisive in the treatment of the asthma with a distinct phenotype 
“obese asthma.” The treatment of this asthma phenotype in children, always, involves an 
attempt with antileukotriene or/and a fixed combination of low dose of inhaled steroid and 
long‐acting beta 2 agonist. The current use of some macrolides, as an anti‐inflammatory drug 
for asthma, is under question now, because it is necessary to make a new assessment of ben‐
efit and harm, or establish a new treatment modality with a combination of macrolides and 
probiotics/synbiotics.
We expect that, in the future, the indications for macrolides, as an anti‐inflammatory drug 
(e.g., for infantile and asthma in childhood), will be accompanied by a recommendation on 
mandatory, simultaneous, and the concomitant application of probiotics or synbiotics, espe‐
cially in the youngest children (Figure 1). The duration of substitution with probiotics or 
synbiotics during and after discontinuation of macrolides should be determined in future 
studies. From our current perspective and findings, and bearing in mind the long‐term dis‐
ruption (24 months) of the intestinal microbiota, we suggest a period of, at least, 9 months 
of probiotics or synbiotics supplementation, which is necessary time for the restitution of 
immune balance between immunoglobulin A and E, in the youngest children [34, 44]. We join 
the recommendation, to avoid all antibiotics, in particular macrolides, for the “irresponsible” 
treatment of viral infections in the youngest children, or several times a year, or longer than 
the prescribed time and doses for macrolides [45] and penicillin [46]. All antibiotics should be 
avoided for one more reason—it is the exclusive way to avoid the intestinal microbiota dis‐
ruption, disorder of the genetic material within the intestinal microbial niches (microbiome), 
metabolic alterations, obesity, immunological imbalance, and early onset of asthma.
We and many other authors worldwide did not end the research for the treatment of asthma 
in obese children, for the “balanced” treatment of the youngest children during respiratory 
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infections, for the overcoming the side effects of some antibiotics in early childhood, for a 
new therapeutic modality, especially in children suffering from wheezing/asthma, respira‐
tory infections and obesity, simultaneously, but this is our future research goal.
Abbreviations
iNKT invariant natural killer T cells
Th T helper cells
IL interleukin
TNF‐alpha tumor necrosis factor‐alpha
INF interferon
nBW normal body weight
TSLP thymic stromal lymphopoietin
ILC2 innate lymhoid cells type 2
DC dendritic cell
IgE immunoglobulin E
FcεRI Fc epsilon RI, the high‐affinity receptor for the Fc region of IgE
PGD2 prostaglandin D2
PAF platelet‐activating factor
TGF transforming growth factor
MAPK mitogen‐activated protein kinase
MEK1 mitogen‐activated protein kinase kinase 1
MEK2 mitogen‐activated protein kinase kinase 2
NF‐kB nuclear factor kappa B
VEGF vascular endothelial growth factor
Areg amphiregulin
mRNA messenger RNA
DNA deoxyribonucleic acid
RNA ribonucleic acid
TLR toll‐like receptor
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ICS inhaled steroids
Vt tidal volume
ATP adenosine triphosphate
FRC functional residual capacity
FEV1 forced expiratory volume in 1 second
FVC forced vital capacity
VO
2
 oxygen consumption
LPS lipopolysaccharide
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